Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
RESEARCH TOOLSreports
Eupraxia Pharmaceuticals (EPRX) Stock Price & Analysis
13 Followers
EPRX Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$3.44 - C$9.10
Previous CloseC$4
Volume32.00K
Average Volume (3M)63.28K
Market Cap
C$144.74M
Enterprise ValueC$109.75M
Total Cash (Recent Filing)C$33.21M
Total Debt (Recent Filing)C$198.76K
Price to Earnings (P/E)-3.2
Beta0.93
Next Earnings
Aug 09, 2024EPS Estimate
-C$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding35,622,553
10 Day Avg. Volume25,518
30 Day Avg. Volume63,278
Standard Deviation0.23
R-Squared0.04
Alpha0.00852
Financial Highlights & Ratios
Price to Book (P/B)8.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$16.50Price Target Upside312.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Eupraxia Pharmaceuticals News
PremiumCompany Announcements
Eupraxia Pharmaceuticals Sets Virtual Shareholder Meeting
PremiumCompany Announcements
Eupraxia Pharmaceuticals Unveils New Study ResultsPremiumCompany Announcements
Eupraxia Reveals Key Study Results at DDW 2024
PremiumCompany Announcements
Eupraxia Pharmaceuticals Sees Assets Grow Despite Losses
PremiumCompany Announcements
Eupraxia Reports Strong Q1 Progress and NASDAQ Listing
PremiumCompany Announcements
Eupraxia Forms Board to Advance EoE Treatment
PremiumCompany Announcements
Eupraxia Pharma Forms GI Advisory Board for EoE DrugOptions Prices
Currently, No data available
---
Ownership Overview
31.69% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
68.31% Public Companies and
Individual Investors
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was C$3.44 and its highest was C$9.10 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Currently, no data Available
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Aug 09, 2024 which is in 81 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -C$0.23.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 35,622,555 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:EPRX
---
Eupraxia Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$16.50 (312.50% Upside)
C$16.50 (312.50% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
149.42%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to approved drugs. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations.
---
EPRX Stock 12 Month Forecast
Average Price Target
C$16.50
▲(312.50% Upside)
Technical Analysis
Best Analysts Covering EPRX
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-34.48%
reiterated a buy rating 2 months ago
Copying Rahul Sarugaser's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.48% per trade.
---